TRADES
Latest Trades
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKG 24 Aug 2022 Buy CDNA CAREDX INC 63,809 0.0487
ARKG 24 Aug 2022 Sell SGFY SIGNIFY HEALTH INC 46,614 0.0476
ARKG 24 Aug 2022 Sell REGN REGENERON PHARMACEUTICALS 1,200 0.0262
ARKG 24 Aug 2022 Buy ATAI ATAI LIFE SCIENCES NV 135,114 0.0220
ARKG 24 Aug 2022 Sell IOVA IOVANCE BIOTHERAPEUTICS INC 23,135 0.0099
ARKG 24 Aug 2022 Buy EXAS EXACT SCIENCES CORP 6,063 0.0080
ARKG 24 Aug 2022 Buy SDGR SCHRODINGER INC 3,959 0.0041
ARKG 24 Aug 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 7,192 0.0029
ARKG 24 Aug 2022 Buy MASS 908 DEVICES INC 1,518 0.0011
ARKG 24 Aug 2022 Sell CGEN COMPUGEN LTD 17,952 0.0008
ARKG 24 Aug 2022 Sell ONEM 1LIFE HEALTHCARE INC 600 0.0004
ARKK 24 Aug 2022 Sell SGFY SIGNIFY HEALTH INC 120,977 0.0423
ARKK 24 Aug 2022 Sell CGEN COMPUGEN LTD 36,390 0.0006
ARKG 23 Aug 2022 Sell SGFY SIGNIFY HEALTH INC 267,226 0.2732
ARKG 23 Aug 2022 Buy EXAS EXACT SCIENCES CORP 127,518 0.1663
ARKG 23 Aug 2022 Sell ONEM 1LIFE HEALTHCARE INC 150,000 0.0958
ARKG 23 Aug 2022 Buy MASS 908 DEVICES INC 107,031 0.0758
ARKG 23 Aug 2022 Buy CMPS COMPASS PATHWAYS PLC 56,139 0.0354
ARKG 23 Aug 2022 Sell IOVA IOVANCE BIOTHERAPEUTICS INC 55,790 0.0242
ARKG 23 Aug 2022 Buy TXG 10X GENOMICS INC 17,706 0.0228
ARKG 23 Aug 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 54,916 0.0209
ARKG 23 Aug 2022 Sell VRTX VERTEX PHARMACEUTICALS INC 1,931 0.0209
ARKG 23 Aug 2022 Buy CDNA CAREDX INC 20,000 0.0151
ARKG 23 Aug 2022 Sell REGN REGENERON PHARMACEUTICALS 617 0.0138
ARKG 23 Aug 2022 Buy BFLY BUTTERFLY NETWORK INC 59,587 0.0117
ARKG 23 Aug 2022 Buy ATAI ATAI LIFE SCIENCES NV 60,967 0.0098
ARKG 23 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 63,360 0.0063
ARKG 23 Aug 2022 Sell CGEN COMPUGEN LTD 11,782 0.0006
ARKK 23 Aug 2022 Buy ZM ZOOM VIDEO COMMUNICATIONS 713,062 0.7316
ARKK 23 Aug 2022 Sell NVDA NVIDIA CORP 231,640 0.4898
ARKK 23 Aug 2022 Sell SGFY SIGNIFY HEALTH INC 687,161 0.2348
ARKK 23 Aug 2022 Buy EXAS EXACT SCIENCES CORP 387,386 0.1689
ARKK 23 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 190,534 0.0063
ARKK 23 Aug 2022 Sell CGEN COMPUGEN LTD 22,921 0.0004
ARKW 23 Aug 2022 Sell NVDA NVIDIA CORP 62,021 0.7364
ARKW 23 Aug 2022 Buy ZM ZOOM VIDEO COMMUNICATIONS 126,239 0.7272
ARKG 22 Aug 2022 Sell SGFY SIGNIFY HEALTH INC 642,230 0.6560
ARKG 22 Aug 2022 Sell ONEM 1LIFE HEALTHCARE INC 342,455 0.2167
ARKG 22 Aug 2022 Buy ADPT ADAPTIVE BIOTECHNOLOGIES 477,498 0.1790
ARKG 22 Aug 2022 Sell VRTX VERTEX PHARMACEUTICALS INC 15,795 0.1704
ARKG 22 Aug 2022 Buy TXG 10X GENOMICS INC 120,658 0.1537
ARKG 22 Aug 2022 Sell REGN REGENERON PHARMACEUTICALS 4,968 0.1109
ARKG 22 Aug 2022 Buy BFLY BUTTERFLY NETWORK INC 583,752 0.1096
ARKG 22 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 834,142 0.0814
ARKG 22 Aug 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIF 277,116 0.0581
ARKG 22 Aug 2022 Buy EXAS EXACT SCIENCES CORP 44,059 0.0564
ARKG 22 Aug 2022 Buy CDNA CAREDX INC 61,580 0.0447
ARKG 22 Aug 2022 Buy CMPS COMPASS PATHWAYS PLC 45,457 0.0277
ARKG 22 Aug 2022 Buy SDGR SCHRODINGER INC 20,483 0.0207
ARKG 22 Aug 2022 Buy ATAI ATAI LIFE SCIENCES NV 130,881 0.0205
ARKG 22 Aug 2022 Buy TDOC TELADOC INC 9,802 0.0116
ARKG 22 Aug 2022 Sell IOVA IOVANCE BIOTHERAPEUTICS INC 20,840 0.0091
ARKG 22 Aug 2022 Buy NVTA INVITAE CORP 73,628 0.0088
ARKG 22 Aug 2022 Buy MASS 908 DEVICES INC 2,900 0.0020
ARKG 22 Aug 2022 Buy NRIX NURIX THERAPEUTICS INC 3,307 0.0018
ARKK 22 Aug 2022 Sell SGFY SIGNIFY HEALTH INC 1,069,686 0.3547
ARKK 22 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 2,504,760 0.0793
ARKK 22 Aug 2022 Buy EXAS EXACT SCIENCES CORP 131,155 0.0545
ARKK 22 Aug 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIF 296,053 0.0202
ARKK 22 Aug 2022 Buy TDOC TELADOC INC 29,363 0.0113
ARKK 22 Aug 2022 Buy NVTA INVITAE CORP 234,023 0.0091
ARKG 19 Aug 2022 Buy SDGR SCHRODINGER INC 52,972 0.0511
ARKG 19 Aug 2022 Buy NRIX NURIX THERAPEUTICS INC 54,852 0.0288
ARKG 19 Aug 2022 Sell SGFY SIGNIFY HEALTH INC 38,803 0.0288
ARKG 19 Aug 2022 Buy SLGC SOMALOGIC INC 97,231 0.0132
ARKK 19 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 848,533 0.0288
ARKK 19 Aug 2022 Sell SGFY SIGNIFY HEALTH INC 119,768 0.0282
ARKF 18 Aug 2022 Sell TWTR TWITTER INC 50 0.0002
ARKG 18 Aug 2022 Buy SDGR SCHRODINGER INC 162,276 0.1556
ARKG 18 Aug 2022 Sell INCY INCYTE CORP 56,037 0.1399
ARKG 18 Aug 2022 Sell ONEM 1LIFE HEALTHCARE INC 224,577 0.1319
ARKG 18 Aug 2022 Sell SGFY SIGNIFY HEALTH INC 76,704 0.0563
ARKG 18 Aug 2022 Buy SLGC SOMALOGIC INC 144,853 0.0199
ARKG 18 Aug 2022 Buy NRIX NURIX THERAPEUTICS INC 32,667 0.0169
ARKG 18 Aug 2022 Buy NVTA INVITAE CORP 116,869 0.0156
ARKG 18 Aug 2022 Sell CGEN COMPUGEN LTD 324,689 0.0155
ARKG 18 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 132,022 0.0141
ARKK 18 Aug 2022 Sell SGFY SIGNIFY HEALTH INC 236,507 0.0549
ARKK 18 Aug 2022 Buy DNA GINKGO BIOWORKS HOLDINGS INC 1,006,821 0.0340
ARKK 18 Aug 2022 Buy NVTA INVITAE CORP 379,287 0.0160
ARKK 18 Aug 2022 Sell CGEN COMPUGEN LTD 643,118 0.0097
ARKF 17 Aug 2022 Buy TDOC TELADOC INC 15,616 0.0527
ARKF 17 Aug 2022 Sell TWTR TWITTER INC 100 0.0004
ARKG 17 Aug 2022 Buy SLGC SOMALOGIC INC 655,956 0.0857
ARKG 17 Aug 2022 Buy TDOC TELADOC INC 66,593 0.0789
ARKG 17 Aug 2022 Sell INCY INCYTE CORP 25,318 0.0603
ARKG 17 Aug 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIF 162,549 0.0400
ARKG 17 Aug 2022 Buy NVTA INVITAE CORP 261,266 0.0358
ARKG 17 Aug 2022 Sell SGFY SIGNIFY HEALTH INC 43,532 0.0306
ARKG 17 Aug 2022 Buy NRIX NURIX THERAPEUTICS INC 231 0.0001
ARKK 17 Aug 2022 Buy TDOC TELADOC INC 196,513 0.0734
ARKK 17 Aug 2022 Buy NVTA INVITAE CORP 850,047 0.0367
ARKK 17 Aug 2022 Sell SGFY SIGNIFY HEALTH INC 95,512 0.0212
ARKK 17 Aug 2022 Buy PACB PACIFIC BIOSCIENCES OF CALIF 177,784 0.0138
ARKQ 17 Aug 2022 Buy MKFG MARKFORGED HOLDING CORP 32,537 0.0072
ARKW 17 Aug 2022 Buy TDOC TELADOC INC 32,351 0.0699
ARKW 17 Aug 2022 Sell TSLA TESLA INC 898 0.0479
ARKX 17 Aug 2022 Buy MKFG MARKFORGED HOLDING CORP 16,397 0.0138
ARKG 16 Aug 2022 Sell INCY INCYTE CORP 47,202 1.6215
ARKG 16 Aug 2022 Buy SLGC SOMALOGIC INC 298,850 0.5616
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.